Cellectar BioSciences Inc. has presented its latest corporate presentation, highlighting the development of Phospholipid Drug Conjugates (PDCs). The company has validated its PDC platform, which shows promise in delivering various oncology therapeutic modalities, including radioisotopes. Notably, their advanced Phospholipid Radioconjugate (PRC), iopofosine I-131, has exceeded efficacy endpoints in a phase 2 study for Waldenstrom's macroglobulinemia $(WM)$. The company has finalized its confirmatory study design and regulatory pathway for potential FDA accelerated approval. Additionally, Cellectar has ongoing studies for other assets, such as CLR 125 and CLR 225, targeting triple-negative breast cancer and pancreatic cancer, respectively. You can access the full presentation through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.